FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clinical trial NCT06909825 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06909825
- Sponsor
- Fusion Pharmaceuticals Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-26
- Primary completion
- 2027-05-01
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.